Inner Mongolia Furui Medical Science Past Earnings Performance
Past criteria checks 5/6
Inner Mongolia Furui Medical Science has been growing earnings at an average annual rate of 29.3%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 7.6% per year. Inner Mongolia Furui Medical Science's return on equity is 7.1%, and it has net margins of 10.7%.
Key information
29.3%
Earnings growth rate
28.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.6% |
| Return on equity | 7.1% |
| Net Margin | 10.7% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Inner Mongolia Furui Medical Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,234 | 132 | 15 | 6 |
| 31 Dec 23 | 1,153 | 103 | 0 | 0 |
| 30 Sep 23 | 1,097 | 110 | 526 | 76 |
| 30 Jun 23 | 1,084 | 109 | 504 | 74 |
| 31 Mar 23 | 1,042 | 102 | 487 | 69 |
| 31 Dec 22 | 1,009 | 98 | 481 | 71 |
| 30 Sep 22 | 1,017 | 98 | 482 | 77 |
| 30 Jun 22 | 960 | 86 | 464 | 70 |
| 31 Mar 22 | 931 | 92 | 444 | 69 |
| 01 Jan 22 | 898 | 95 | 415 | 65 |
| 30 Sep 21 | 848 | 90 | 371 | 57 |
| 30 Jun 21 | 832 | 89 | 366 | 61 |
| 31 Mar 21 | 780 | 64 | 348 | 63 |
| 31 Dec 20 | 808 | 62 | 363 | 66 |
| 30 Sep 20 | 817 | 50 | 389 | 65 |
| 30 Jun 20 | 808 | 42 | 397 | 61 |
| 31 Mar 20 | 862 | 47 | 385 | 67 |
| 31 Dec 19 | 832 | 43 | 378 | 61 |
| 30 Sep 19 | 858 | 1 | 415 | 74 |
| 30 Jun 19 | 865 | 3 | 410 | 77 |
| 31 Mar 19 | 866 | 32 | 411 | 67 |
| 31 Dec 18 | 867 | 35 | 406 | 65 |
| 30 Sep 18 | 824 | 71 | 343 | 64 |
| 30 Jun 18 | 799 | 70 | 305 | 81 |
| 31 Mar 18 | 844 | 63 | 372 | 71 |
| 31 Dec 17 | 823 | 61 | 381 | 60 |
| 30 Sep 17 | 882 | 117 | 415 | 31 |
| 30 Jun 17 | 886 | 117 | 443 | 0 |
| 31 Mar 17 | 858 | 121 | 423 | 0 |
| 31 Dec 16 | 827 | 121 | 407 | 0 |
| 30 Sep 16 | 709 | 100 | 350 | 0 |
| 30 Jun 16 | 671 | 99 | 336 | 0 |
| 31 Mar 16 | 608 | 92 | 287 | 0 |
| 31 Dec 15 | 604 | 92 | 277 | 0 |
| 30 Sep 15 | 649 | 90 | 295 | 0 |
| 30 Jun 15 | 668 | 108 | 289 | 0 |
| 31 Mar 15 | 634 | 90 | 280 | 0 |
| 31 Dec 14 | 646 | 87 | 279 | 0 |
| 30 Sep 14 | 567 | 39 | 270 | 0 |
| 30 Jun 14 | 564 | 15 | 274 | 0 |
| 31 Mar 14 | 533 | 7 | 257 | 0 |
| 31 Dec 13 | 523 | 5 | 256 | 0 |
| 30 Sep 13 | 516 | 6 | 261 | 0 |
| 30 Jun 13 | 464 | 18 | 240 | 0 |
Quality Earnings: 300049 has high quality earnings.
Growing Profit Margin: 300049's current net profit margins (10.7%) are higher than last year (9.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300049's earnings have grown significantly by 29.3% per year over the past 5 years.
Accelerating Growth: 300049's earnings growth over the past year (29.4%) exceeds its 5-year average (29.3% per year).
Earnings vs Industry: 300049 earnings growth over the past year (29.4%) exceeded the Pharmaceuticals industry -1.5%.
Return on Equity
High ROE: 300049's Return on Equity (7.1%) is considered low.